Skip to main content
. Author manuscript; available in PMC: 2016 Apr 25.
Published in final edited form as: Vaccine. 2014 May 14;32(30):3780–3786. doi: 10.1016/j.vaccine.2014.05.014

Figure 3.

Figure 3

Overall reduction in the annual number of cCMV infections at equilibrium by proportion of individuals effectively vaccinated by age at vaccination, assuming age-specific duration of infectiousness, 20 year duration of latency, and a vaccine with 5-year duration of protection, United States and Brazil.